Loading…
← CockpitCompetitor Analysis › APN.L Applied Nutrition PLCOpen in the cockpit ↗

Applied Nutrition PLCAPN.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Pharmaceuticals: Other
Momentum strong 71
Mkt cap
$986M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$2.43M
20-day average traded
Fwd P/E
21.4×
forward earnings
ROIC−WACC
+25.9 pp
WACC 15.5%
Hurdle
-14 pp
Req g minus delivered
Next earnings
145 days
12 Apr 2027
Close · GBP£300.00
1D+0.8%
1W-1.0%
1M+3.6%
3M-6.0%
6M+31.0%
YTD+19.1%
1Y+79.9%
ATR %4.1%
52w lowhigh15.7% off high

What Applied Nutrition does

No business profile yet.

Applied Nutrition at a glance

Size Applied Nutrition (APN.L) is a United Kingdom Health Care company (Pharmaceuticals: Other) with a market value of $986M, the 215th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £300.00 on 18 Nov 2026.

Performance Over six months the shares gained 31.0%, against -17.5% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 50.9% over the last twelve months (peer median +4.8%); the operating margin is 25.1% (peer median 14.0%).

Valuation It trades at 21.4× forward earnings against a peer median of 18.1× (7th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +39%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 25.9 points above its cost of capital (15.5% WACC).

Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026APN.L 129Peer median 84
Six months, rebased to 100: Applied Nutrition against the median of its 20 peers (local-currency closes).

Applied Nutrition financials

Reported figures in GBP; fiscal year ends 2026-07-31. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue£162M£162M£107M£86.2M£60.8M
Revenue growth—+51%+24%+42%—
Gross profit£69.6M£69.6M£48.2M£40.4M£26.5M
EBITDA£42.3M£42.3M£30.9M£25.8M£18.5M
Net income£30.6M£30.6M£21.1M£18.7M£13.8M
Free cash flow£10.6M£10.6M£15.2M£6.28M£7.62M
Capital expenditure£2.00M£2.00M£1.00M£1.06M£1.00M
Total debtn/a£4.00M£3.00M£1.80M£2.06M

Quarterly statements and history in the cockpit →

Applied Nutrition competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%000756002219002275PHN21420460603262CRONPHMBIOG-B64722877300791JWEL600488300039SUDEEPPHRM002562600216APN.L6-month return →1-month return →
Up and to the right = strong over both horizons. Applied Nutrition is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×000756002219002275PHN21420460603262CRONPHMBIOG-B64722877300791JWELSUDEEPPHRMAPN.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Applied Nutrition is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%000756002275PHN2142603262CRONPHMBIOG-B6472300791JWEL600488300039600216APN.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Applied Nutrition is the large dot.

Applied Nutrition competitors and peer comparison

How Applied Nutrition compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Applied Nutrition against its 20 peers (data as of 18 Nov 2026)
MeasureAPN.LPeer medianRank in peer set
1-month return+3.6%-7.3%4th highest of 21
6-month return+31.0%-17.5%3rd highest of 21
Distance from 52-week high-15.7%-37.3%5th highest of 21
Revenue growth (TTM)+50.9%+4.8%3rd highest of 21
Operating margin25.1%14.0%4th highest of 21
Forward P/E21.4×18.1×7th most expensive of 17
Growth the price implies (Req g, 7 yrs)24.6%4.0%most demanding of 16
Growth delivered (Del g)+38.5%+13.5%3rd highest of 16
Hurdle (Req g minus delivered)-13.9 pp-8.0 pp5th least demanding of 16
ROIC minus cost of capital+25.9 pp+1.5 pp5th highest of 21
EV / EBITDA17.4×18.9×5th cheapest of 10
Net debt / EBITDA-0.3×-1.5×5th most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a

Questions

Which companies are Applied Nutrition's closest peers?
The cockpit's peer set: Shandong Xinhua Pharmaceutical (000756.SZ), New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), Guilin Sanjin Pharmaceutical (002275.SZ), PharmaNutra (PHN.MI), HBM (2142.HK), Sihuan Pharmaceutical (0460.HK), TSI (603262.SS), Cronos (CRON.TO).
Is Applied Nutrition expensive compared with its peers?
On forward p/e it trades at 21.4× against a peer median of 18.1×, 7th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +39%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Applied Nutrition stock performed?
Over six months to 18 Nov 2026 the shares returned +31.0% against -17.5% for the median peer; over one year +79.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.